IFNA1 and infection: This open-label study was designed to provide access to simeprevir treatment in combination with PegIFNα-2a and RBV for a well characterized treatment-experienced patient population with HCV GT1 infection in terms of baseline characteristics and prior response to PegIFN/RBV, after they had completed participation in a prior study and at a time when current therapeutic IFN-free alternatives were not yet available.